Skip to Content Skip to Navigation
30th January 2020 Prostate Cancer

New Drug Discoveries For Prostate Cancer

Professor Wayne Tilley

Known and new drugs heading to clinical and preclinical trials.

A local research team has made a major leap forward in identifying new drugs to treat prostate cancer, bringing hope to the many men suffering from this awful disease.

With support from THRF Group charity Australian Prostate Cancer, Professor Wayne Tilley and his team at the Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, have tested a series of existing drugs (already approved for use in people but not being used to treat prostate cancer) PLUS potential new drugs (not yet tested in people) to see which ones show promise in changing an offending hormone receptor from cancer-promoting to cancer-inhibiting.

The team has now identified an exciting list of known and new drugs to take forward!

“This rapid translation of our work into the clinical arena illustrates the power of finding a new purpose for drugs developed for one disease that may be useful for the treatment of another disease,” Prof Tilley said.

“For the known drugs, we are now working to present the final evidence necessary to design and establish clinical trials to test their efficacy in patients.

“For the potential new drugs, we will now embark on a drug development phase and preclinical testing to ensure they have optimal drug properties and are non-toxic before being tested in people.”

The work is helping to save even more lives, with it also being applied to breast cancer in collaboration with Associate Professor Theresa Hickey.

“We have already advanced one known drug candidate for breast cancer. The work related to breast cancer is being considered for publication in a highly esteemed scientific journal and we have commenced a clinical trial. The work related to prostate cancer is being prepared for publication and discussions are underway for clinical trial design,” Prof Tilley said.

“In addition to these clinical outcomes, the project has produced a wealth of new information and data that will be shared with researchers worldwide via publication and deposit of data into public repositories.

“By the end of this project, we aim to have at least three scientific publications describing our work and its results, to have designed at least one clinical trial involving a repurposed drug for breast or prostate cancer, and have at least one new drug enter the drug development pipeline.”

If you wish to support much-needed research into prostate cancer, find out more here.

Donate